Correction to Small Molecule Inhibitors of Bromodomain-Acetyl-lysine Interactions (ACS Chem. Biol. (2015) 10:1 (22-39) DOI: 10.1021/cb500996u);Small molecule inhibitors of bromodomain - Acetyl-lysine interactions

ACS Chemical Biology

Volumn 10, Issue 1, 2015, Pages 22-39

  Brand, Michael ^a   Measures, Angelina M ^a   Wilson, Brian G ^a   Cortopassi, Wilian A ^a   Alexander, Rikki ^b   Höss, Matthias ^b   Hewings, David S ^a   Rooney, Timothy P C ^a   Paton, Robert S ^a   Conway, Stuart J ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UCB Group   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXY N (1,2,3,4 TETRAHYDRO 3 METHYL 2 OXO 6 QUINAZOLINYL)BENZENESULFONAMIDE; 2 MORPHOLINO 8 PHENYLCHROMONE; ACETYL LYSINE; APABETALONE; AZOBENZENE DERIVATIVE; BROMODOMAIN INHIBITOR; DIAZEPINE DERIVATIVE; DIBENZOXAZEPINE DERIVATIVE; GSK1324726A; LYSINE; OXAZOLE DERIVATIVE; PYRROLE DERIVATIVE; QUINOXALINE DERIVATIVE; THIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; HISTONE; LIGAND; MOLECULAR LIBRARY; NUCLEAR PROTEIN; PROTEIN BINDING;

AUTOIMMUNE DISEASE; CARCINOGENESIS; CELL VIABILITY; COMPUTER MODEL; CROHN DISEASE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LUNG ADENOCARCINOMA; LUNG CANCER CELL LINE; MOLECULAR DOCKING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; ULCERATIVE COLITIS; VIRTUAL REALITY; ACETYLATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECTS; GENETICS; METABOLISM; MOLECULAR LIBRARY; PHARMACOLOGY; PROTEIN PROCESSING; PROTEIN TERTIARY STRUCTURE; STRUCTURE ACTIVITY RELATION;

ACETYLATION; ANIMALS; HISTONES; HUMANS; LIGANDS; LYSINE; MODELS, MOLECULAR; NUCLEAR PROTEINS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTEIN STRUCTURE, TERTIARY; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84921284940     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/acschembio.5b01065     Document Type: Erratum

References (138)

1. Allfrey, V. G., Faulkner, R., and Mirsky, A. E. (1964) Acetylation and methylation of histones and their possible role in the regulation of RNA synthesis. Proc. Natl. Acad. Sci. U.S.A. 51, 786-794.
2. Gershey, E. L., Vidali, G., and Allfrey, V. G. (1968) Chemical studies of histone acetylation. J. Biol. Chem. 243, 5018-5022.
3. Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., and Mann, M. (2009) Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 325, 834-840.
4. Brownell, J. E., Zhou, J., Ranalli, T., Kobayashi, R., Edmondson, D. G., Roth, S. Y., and Allis, C. D. (1996) Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p linking histone acetylation to gene activation. Cell 84, 843-851.
5. Taunton, J., Hassig, C. A., and Schreiber, S. L. (1996) A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p. Science 272, 408-411.
6. Dhalluin, C., Carlson, J. E., Zeng, L., He, C., Aggarwal, A. K., and Zhou, M.-M. (1999) Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491-496.
7. Winston, F., and Allis, C. D. (1999) The bromodomain: a chromatin-targeting module? Nat. Struct. Biol. 6, 601-604.
8. Mujtaba, S., He, Y., Zeng, L., Yan, S., Plotnikova, O., Sachchidanand, Sanchez, R., Zeleznik-Le, N. J., Ronai, Z., and Zhou, M.-M. (2004) Structural mechanism of the bromodomain of the coactivator CBP in p53 transcriptional activation. Mol. Cell 13, 251-263.
9. Kouzarides, T. (2000) Acetylation: a regulatory modification to rival phosphorylation? EMBO J. 19, 1176-1179.
10. Choudhary, C., Weinert, B. T., Nishida, Y., Verdin, E., and Mann, M. (2014) The growing landscape of lysine acetylation links metabolism and cell signalling. Nat. Rev. Mol. Cell Biol. 15, 536-550.
11. Strahl, B. D., and Allis, C. D. (2000) The language of covalent histone modifications. Nature 403, 41-45.
12. Gardner, K. E., Allis, C. D., and Strahl, B. D. (2011) Operating on chromatin, a colorful language where context matters. J. Mol. Biol. 409, 36-46.
13. Filippakopoulos, P., and Knapp, S. (2014) Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discovery 13, 337-356.
14. Filippakopoulos, P., Picaud, S., Mangos, M., Keates, T., Lambert, J.-P., Barsyte-Lovejoy, D., Felletar, I., Volkmer, R., Müller, S., Pawson, T., Gingras, A.-C., Arrowsmith, C. H., and Knapp, S. (2012) Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214-231.
15. Wilson, A. J. (2009) Inhibition of protein-protein interactions using designed molecules. Chem. Soc. Rev. 38, 3289-3300.
16. Hewings, D. S., Rooney, T. P. C., Jennings, L. E., Hay, D., Schofield, C. J., Brennan, P. E., Knapp, S., and Conway, S. J. (2012) Progress in the development and application of small molecule inhibitors of bromodomain-acetyl-lysine interactions. J. Med. Chem. 55, 9393-9413.
17. Jennings, L. E., Measures, A. R., Wilson, B. G., and Conway, S. J. (2014) Phenotypic screening and fragment-based approaches to the discovery of small-molecule bromodomain ligands. Future Med. Chem. 6, 179-204.
18. Garnier, J.-M., Sharp, P. P., and Burns, C. J. (2014) BET bromodomain inhibitors: a patent review. Expert Opin. Ther. Pat. 24, 185-199.
19. Gallenkamp, D., Gelato, K. A., Haendler, B., and Weinmann, H. (2014) Bromodomains and their pharmacological inhibitors. ChemMedChem 9, 438-464.
20. Jang, M. K., Mochizuki, K., Zhou, M., Jeong, H.-S., Brady, J. N., and Ozato, K. (2005) The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription. Mol. Cell 19, 523-534.
21. Gaucher, J., Boussouar, F., Montellier, E., Curtet, S., Buchou, T., Bertrand, S., Hery, P., Jounier, S., Depaux, A., Vitte, A.-L., Guardiola, P., Pernet, K., Debernardi, A., Lopez, F., Holota, H., Imbert, J., Wolgemuth, D. J., Gérard, M., Rousseaux, S., and Khochbin, S. (2012) Bromodomain-dependent stage-specific male genome programming by Brdt. EMBO J. 31, 3809-3820.
22. Mujtaba, S., He, Y., Zeng, L., Farooq, A., Carlson, J. E., Ott, M., Verdin, E., and Zhou, M.-M. (2002) Structural basis of lysine-acetylated HIV-1 Tat recognition by PCAF bromodomain. Mol. Cell 9, 575-586.
23. Pan, C., Mezei, M., Mujtaba, S., Muller, M., Zeng, L., Li, J., Wang, Z., and Zhou, M.-M. (2007) Structure-guided optimization of small molecules inhibiting human immunodeficiency virus 1 Tat association with the human coactivator p300/CREB binding protein-associated factor. J. Med. Chem. 50, 2285-2288.
24. Filippakopoulos, P., Qi, J., Picaud, S., Shen, Y., Smith, W. B., Fedorov, O., Morse, E. M., Keates, T., Hickman, T. T., Felletar, I., Philpott, M., Munro, S., McKeown, M. R., Wang, Y., Christie, A. L., West, N., Cameron, M. J., Schwartz, B., Heightman, T. D., La Thangue, N., French, C. a, Wiest, O., Kung, A. L., Knapp, S., and Bradner, J. E. (2010) Selective inhibition of BET bromodomains. Nature 468, 1067-1073.
25. Nicodeme, E., Jeffrey, K. L., Schaefer, U., Beinke, S., Dewell, S., Chung, C.-W., Chandwani, R., Marazzi, I., Wilson, P., Coste, H., White, J., Kirilovsky, J., Rice, C. M., Lora, J. M., Prinjha, R. K., Lee, K., and Tarakhovsky, A. (2010) Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123.
26. Bunin, B. A., Plunkett, M. J., and Ellman, J. A. (1994) The combinatorial synthesis and chemical and biological evaluation of a 1,4-benzodiazepine library. Proc. Natl. Acad. Sci. U.S.A. 91, 4708-4712.
27. Wu, X., and Schultz, P. G. (2009) Synthesis at the interface of chemistry and biology. J. Am. Chem. Soc. 131, 12497-12515.
28. Mirguet, O., Gosmini, R., Toum, J., Clement, C. A., Melanie, B., Brusq, J., Mordaunt, J. E., Grimes, R. M., Crowe, M., Pineau, O., Ajakane, M., Daugan, A., Jeffrey, P., Cutler, L., Haynes, A. C., Smithers, N. N., Chung, C., Bamborough, P., Uings, I. J., Lewis, A., Witherington, J., Parr, N., Prinjha, R. K., and Nicodeme, E. (2013) Discovery of epigenetic regulator I-BET762: lead optimization to afford a clinical candidate inhibitor of the BET bromodomains. J. Med. Chem. 56, 7501-7515.
29. Chung, C.-W., Coste, H., White, J. H., Mirguet, O., Wilde, J., Gosmini, R. L., Delves, C., Magny, S. M., Woodward, R., Hughes, S. a, Boursier, E. V., Flynn, H., Bouillot, A. M., Bamborough, P., Brusq, J.-M. G., Gellibert, F. J., Jones, E. J., Riou, A. M., Homes, P., Martin, S. L., Uings, I. J., Toum, J., Clement, C. a, Boullay, A.-B., Grimley, R. L., Blandel, F. M., Prinjha, R. K., Lee, K., Kirilovsky, J., and Nicodeme, E. (2011) Discovery and characterization of small molecule inhibitors of the BET family bromodomains. J. Med. Chem. 54, 3827-3838.
30. Chiba, K., Manabe, S., Moriwaki, M., Nakagawa, T., Nakamura, T., Shindo, M., and Tahara, T. (1996) Therapeutic agent for osteoporosis and diazepine compound. US5753649A.
31. Miyoshi, S., Ooike, S., Iwata, K., Hikwa, H., Sugahara, K., Hikwawa, H., and Sugahara, K. (2009) Antitumor agent. WO2009084693.
32. Adachi, K., Hikwawa, H., Hamada, M., Endoh, J., Ishibuchi, S., Fujie, N., Tanaka, M., Sugahara, K., Kouichi, O., and Murata, M. (2006) Thienotriazolodiazepine compound and a medicinal use thereof. WO2006129623.
33. Noel, J. K., Iwata, K., Ooike, S., Sugahara, K., Nakamura, H., and Daibata, M. (2013) Mol. Cancer Ther. 12 (11 Suppl), C244.
34. Schmees, N., Kuhnke, J., Haendler, B., Neuhaus, R., Lejeune, P., Siegel, S., Krüger, S., Ernesto, A., Künzer, H., and Gallenkamp, D. (2014) Bet protein-inhibiting 5-aryl triazole azepines. WO2014048945.
35. Zhang, G., Liu, R., Zhong, Y., Plotnikov, A. N., Zhang, W., Zeng, L., Rusinova, E., Gerona-Nevarro, G., Moshkina, N., Joshua, J., Chuang, P. Y., Ohlmeyer, M., He, J. C., and Zhou, M.-M. (2012) Downregulation of NF-κB transcriptional activity in HIV-associated kidney disease by BRD4 inhibition. J. Biol. Chem. 287, 28840-28851.
36. Arnold, L. D., Foreman, K. W., and Werner, D. S. (2013) Bromodomain ligands capable of dimerizing in an aqueous solution, and methods of using same. WO2013033270.
37. Hewings, D. S., Wang, M., Philpott, M., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Vuppusetty, C., Marsden, B., Knapp, S., Conway, S. J., and Heightman, T. D. (2011) 3,5-Dimethylisoxazoles act as acetyl-lysine-mimetic bromodomain ligands. J. Med. Chem. 54, 6761-6770.
38. Dawson, M. a, Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C., Hopf, C., Savitski, M. M., Huthmacher, C., Gudgin, E., Lugo, D., Beinke, S., Chapman, T. D., Roberts, E. J., Soden, P. E., Auger, K. R., Mirguet, O., Doehner, K., Delwel, R., Burnett, A. K., Jeffrey, P., Drewes, G., Lee, K., Huntly, B. J. P., and Kouzarides, T. (2011) Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature 478, 529-533.
39. Bamborough, P., Diallo, H., Goodacre, J. D., Gordon, L., Lewis, A., Seal, J. T., Wilson, D. M., Woodrow, M. D., and Chung, C. (2012) Fragment-based discovery of bromodomain inhibitors part 2: optimization of phenylisoxazole sulfonamides. J. Med. Chem. 55, 587-596.
40. Mirguet, O., Lamotte, Y., Donche, F., Toum, J., Gellibert, F., Bouillot, A., Gosmini, R., Nguyen, V.-L., Delannée, D., Seal, J., Blandel, F., Boullay, A.-B., Boursier, E., Martin, S., Brusq, J.-M., Krysa, G., Riou, A., Tellier, R., Costaz, A., Huet, P., Dudit, Y., Trottet, L., Kirilovsky, J., and Nicodeme, E. (2012) From ApoA1 upregulation to BET family bromodomain inhibition: discovery of I-BET151. Bioorg. Med. Chem. Lett. 22, 2963-2967.
41. Seal, J., Lamotte, Y., Donche, F., Bouillot, A., Mirguet, O., Gellibert, F., Nicodeme, E., Krysa, G., Kirilovsky, J., Beinke, S., McCleary, S., Rioja, I., Bamborough, P., Chung, C.-W., Gordon, L., Lewis, T., Walker, A. L., Cutler, L., Lugo, D., Wilson, D. M., Witherington, J., Lee, K., and Prinjha, R. K. (2012) Identification of a novel series of BET family bromodomain inhibitors: binding mode and profile of I-BET151 (GSK1210151A). Bioorg. Med. Chem. Lett. 22, 2968-2972.
42. Hewings, D. S., Fedorov, O., Filippakopoulos, P., Martin, S., Picaud, S., Tumber, A., Wells, C., Olcina, M. M., Freeman, K., Gill, A., Ritchie, A. J., Sheppard, D. W., Russell, A. J., Hammond, E. M., Knapp, S., Brennan, P. E., and Conway, S. J. (2013) Optimization of 3,5-dimethylisoxazole derivatives as potent bromodomain ligands. J. Med. Chem. 56, 3217-3227.
43. Gehling, V. S., Hewitt, M. C., Vaswani, R. G., Leblanc, Y., Co, A., Nasveschuk, C. G., Taylor, A. M., Harmange, J., Audia, J. E., Pardo, E., Joshi, S., Sandy, P., Mertz, J. A., Sims, R. J., Bergeron, L., Bryant, B. M., Bellon, S., Poy, F., Jayaram, H., Sankaranarayanan, R., Yellapantula, S., Srinivasamurthy, N. B., Birudukota, S., and Albrecht, B. K. (2013) Discovery, design, and optimization of isoxazole azepine BET inhibitors. ACS Med. Chem. Lett. 4, 835-840.
44. Hay, D., Fedorov, O., Filippakopoulos, P., Martin, S., Philpott, M., Picaud, S., Hewings, D. S., Uttakar, S., Heightman, T. D., Conway, S. J., Knapp, S., and Brennan, P. E. (2013) The design and synthesis of 5-and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains. MedChemComm 4, 140-144.
45. Hay, D., Fedorov, O., Martin, S., Singleton, D. C., Tallant, C., Wells, C., Picaud, S., Philpott, M., Monteiro, O. P., Rogers, C. M., Conway, S. J., Rooney, T. P. C., Tumber, A., Yapp, C., Filippakopoulos, P., Bunnage, M. E., Müller, S., Knapp, S., Schofield, C. J., and Brennan, P. E. (2014) Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J. Am. Chem. Soc. 136, 9308-9319.
46. Sharp, P. P., Garnier, J.-M., Huang, D. C. S., and Burns, C. J. (2014) Evaluation of functional groups as acetyl-lysine mimetics for BET bromodomain inhibition. Med. Chem. Commun. 5, 1834-1842.
47. Picaud, S., Wells, C., Felletar, I., Brotherton, D., Martin, S., and Savitsky, P. (2013) RVX-208, an inhibitor of BET transcriptional regulators with selectivity for the second bromodomain. Proc. Natl. Acad. Sci. U.S.A. 110, 19754-19759.
48. McLure, K. G., Gesner, E. M., Tsujikawa, L., Kharenko, O. a, Attwell, S., Campeau, E., Wasiak, S., Stein, A., White, A., Fontano, E., Suto, R. K., Wong, N. C. W., Wagner, G. S., Hansen, H. C., and Young, P. R. (2013) RVX-208, an inducer of ApoA-I in humans, is a BET bromodomain antagonist. PLoS One 8, e83190.
49. Bailey, D., Jahagirdar, R., Gordon, A., Hafiane, A., Campbell, S., Chatur, S., Wagner, G. S., Hansen, H. C., Chiacchia, F. S., Johansson, J., Krimbou, L., Wong, N. C. W., and Genest, J. (2010) RVX-208: a small molecule that increases apolipoprotein A-1 and high-density lipoprotein cholesterol in vitro and in vivo. J. Am. Coll. Cardiol. 55, 2580-2589.
50. Nicholls, S. J., Gordon, A., Johansson, J., Wolski, K., Ballantyne, C. M., Kastelein, J. J. P., Taylor, A., Borgman, M., and Nissen, S. E. (2011) Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J. Am. Coll. Cardiol. 57, 1111-9.
51. Chung, C.-W., Dean, A. W., Woolven, J. M., and Bamborough, P. (2012) Fragment-based discovery of bromodomain inhibitors part 1: inhibitor binding modes and implications for lead discovery. J. Med. Chem. 55, 576-586.
52. Philpott, M., Yang, J., Tumber, T., Fedorov, O., Uttarkar, S., Filippakopoulos, P., Picaud, S., Keates, T., Felletar, I., Ciulli, A., Knapp, S., and Heightman, T. D. (2011) Bromodomain-peptide displacement assays for interactome mapping and inhibitor discovery. Mol. Biosyst. 7, 2899-2908.
53. Fish, P. V., Filippakopoulos, P., Bish, G., Brennan, P. E., Bunnage, M. E., Cook, A. S., Federov, O., Gerstenberger, B. S., Jones, H., Knapp, S., Marsden, B., Nocka, K., Owen, D. R., Philpott, M., Picaud, S., Primiano, M. J., Ralph, M. J., Sciammetta, N., and Trzupek, J. D. (2012) Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J. Med. Chem. 55, 9831-9837.
54. Picaud, S., Da Costa, D., Thanasopoulou, A., Filippakopoulos, P., Fish, P. V., Philpott, M., Fedorov, O., Brennan, P., Bunnage, M. E., Owen, D. R., Bradner, J. E., Taniere, P., O'Sullivan, B., Muller, S., Schwaller, J., Stankovic, T., and Knapp, S. (2013) PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res. 73, 3336-3346.
55. Zhao, L., Cao, D., Chen, T., Wang, Y., Miao, Z., Xu, Y., He, J., and Shen, J. (2013) Fragment-based drug discovery of 2-thiazolidinones as inhibitors of the histone reader BRD4 bromodomain. J. Med. Chem. 56, 3833-3851.
56. Borah, J. C., Mujtaba, S., Karakikes, I., Zeng, L., Muller, M., Patel, J., Moshkina, N., Morohashi, K., Zhang, W., Gerona-Navarro, G., Hajjar, R. J., and Zhou, M.-M. (2011) A small molecule binding to the coactivator CREB-binding protein blocks apoptosis in cardiomyocytes. Chem. Biol. 18, 531-541.
57. Zhang, G., Plotnikov, A. N., Rusinova, E., Shen, T., Morohashi, K., Joshua, J., Zeng, L., Mujtaba, S., Ohlmeyer, M., and Zhou, M.-M. (2013) Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains. J. Med. Chem. 56, 9251-9264.
58. Zhou, M. M., Ohlmeyer, M., Mujtaba, S., Plotnikov, A., Kastrinsky, D., and Zhang, G. (2012) Inhibitors of bromodomains as modulators of gene expression. WO2012116170.
59. Lucas, X., Wohlwend, D., Hügle, M., Schmidtkunz, K., Gerhardt, S., Schüle, R., Jung, M., Einsle, O., and Günther, S. (2013) 4-Acyl pyrroles: mimicking acetylated lysines in histone code reading. Angew. Chem., Int. Ed. 52, 14055-14059.
60. Demont, H. E., and Gosmini, R. L. M. (2011) Thetrahydroquinolines derivatives as bromodomain inhibitors. WO2011054848.
61. Wyce, A., Ganji, G., Smitheman, K. N., Chung, C.-W., Korenchuk, S., Bai, Y., Barbash, O., Le, B., Craggs, P. D., McCabe, M. T., Kennedy-Wilson, K. M., Sanchez, L. V., Gosmini, R. L., Parr, N., McHugh, C. F., Dhanak, D., Prinjha, R. K., Auger, K. R., and Tummino, P. J. (2013) BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One 8, e72967.
62. Gosmini, R., Nguyen, V. L., Toum, J., Simon, C., Brusq, J. G., Krysa, G., Mirguet, O., Riou-eymard, A. M., Boursier, E. V., Trottet, L., Bamborough, P., Clark, H., Chung, C., Cutler, L., Demont, E. H., Kaur, R., Lewis, A. J., Schilling, M. B., Soden, P. E., Taylor, S., Walker, A. L., Walker, M. D., Prinjha, R. K., and Nicodeme, E. (2014) The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 upregulator and selective BET bromodomain inhibitor. J. Med. Chem. 57, 8111-8131.
63. Martin, M. P., Olesen, S. H., Georg, G. I., and Schönbrunn, E. (2013) Cyclin-dependent kinase inhibitor dinaciclib interacts with the acetyl-lysine recognition site of bromodomains. ACS Chem. Biol. 8, 2360-2365.
64. Dittmann, A., Werner, T., Chung, C., Savitski, M. M., Fa, M., Grandi, P., Hopf, C., Lindon, M., Neubauer, G., Prinjha, R. K., Bantsche, M., and Drewes, G. (2014) The commonly used PI3-kinase probe LY294002 is an inhibitor of BET bromodomains. ACS Chem. Biol. 9, 495-502.
65. Devaiah, B. N., Lewis, B. A., Cherman, N., Hewitt, M. C., Albrecht, B. K., Robey, P. G., Ozato, K., Sims, R. J., and Singer, D. S. (2012) BRD4 is an atypical kinase that phosphorylates serine 2 of the RNA polymerase II carboxy-terminal domain. Proc. Natl. Acad. Sci. U.S.A. 109, 6927-6932.
66. Gharbi, S. I., Zvelebil, M. J., Shuttleworth, S. J., Hancox, T., Saghir, N., Timms, J. F., and Waterfield, M. D. (2007) Exploring the specificity of the PI3K family inhibitor LY294002. Biochem. J. 404, 15-21.
67. Kim, Y. H., Choi, K.-H., Park, J.-W., and Kwon, T. K. (2005) LY294002 inhibits LPS-induced NO production through a inhibition of NF-kappaB activation: independent mechanism of phosphatidylinositol 3-kinase. Immunol. Lett. 99, 45-50.
68. Huang, B., Yang, X.-D., Zhou, M.-M., Ozato, K., and Chen, L.-F. (2009) Brd4 coactivates transcriptional activation of NF-kappaB via specific binding to acetylated RelA. Mol. Cell. Biol. 29, 1375-87.
69. Zou, Z., Huang, B., Wu, X., Zhang, H., Qi, J., Bradner, J., Nair, S., and Chen, L.-F. (2014) Brd4 maintains constitutively active NF-κB in cancer cells by binding to acetylated RelA. Oncogene 33, 2395-2404.
70. Ciceri, P., Müller, S., O'Mahony, A., Fedorov, O., Filippakopoulos, P., Hunt, J. P., Lasater, E. a, Pallares, G., Picaud, S., Wells, C., Martin, S., Wodicka, L. M., Shah, N. P., Treiber, D. K., and Knapp, S. (2014) Dual kinase-bromodomain inhibitors for rationally designed polypharmacology. Nat. Chem. Biol. 10, 305-312.
71. Ember, S. W. J., Zhu, J., Olesen, S. H., Martin, M. P., Becker, A., Berndt, N., Georg, G. I., and Scho, E. (2014) Acetyl-lysine binding site of bromodomain-containing protein 4 (BRD4) interacts with diverse kinase inhibitors. ACS Chem. Biol. 9, 1160-1171.
72. Baud, M. G. J., Lin-Shiao, E., Cardote, T., Tallant, C., Pschibul, A., Chan, K.-H., Zengerle, M., Garcia, J. R., Kwan, T. T.-L., Ferguson, F. M., and Ciulli, A. (2014) A bump-and-hole approach to engineer controlled selectivity of BET bromodomain chemical probes. Science 346, 638-641.
73. Bishop, A., Buzko, O., Jung, I., Kraybill, B., Liu, Y., Shah, K., Ulrich, S., Witucki, L., Yang, F., Zhang, C., and Shokat, K. M. (2000) Unnatural ligands for engineered proteins: new tools for chemical genetics. Annu. Rev. Biophys. Biomol. Struct. 29, 577-606.
74. Amans, D., Bamborough, P., Bit, R. A., Brown, J. A., Campbell, M., Lindon, M. J., Shipley, T. J., Theodoulou, N. H., Wellaway, C. R., and Westaway, S. M. (2014) Thieno[3,2-c]pyridin-4(5h)-ones as BET inhibitors. WO2014078257.
75. Amans, D., Atkinson, S. J., Harrison, L. A., Hirst, D. J., Law, R. P., Lindon, M., Preston, A., Seal, J. T., and Wellaway, C. R. (2014) 2,3-disubstituted 1-acyl-4-amino-1,2,3,4-tetrahydroquinoline derivatives and their use as bromodomain inhibitors. WO2014140076.
76. Amans, D., Bamborough, P., Barker, M. D., Bit, R. A., Brown, J. A., Campbell, M.; Garton, N. S., Lindon, M. J., Shipley, T. J., Theodoulou, N. H., Wellaway C. R., and Westaway S. M. (2014) Furopyridines as bromodomain inhibitors. WO2014140077.
77. Wang, L., Pratt, J. K., McDaniel, K. F., Dai, Y., Fidanze, S. D., Hasvold, L., Holms, J. H., Kati, W. M., Liu, D., Mantei, R. A., McClellan, W. J., Sheppard, G. S., and Wada, C. K. (2014) Bromodomain inhibitors. US20140162971.
78. Crawford, N. P. S., Alsarraj, J., Lukes, L., Walker, R. C., Officewala, J. S., Yang, H. H., Lee, M. P., Ozato, K., and Hunter, K. W. (2008) Bromodomain 4 activation predicts breast cancer survival. Proc. Natl. Acad. Sci. U.S.A. 105, 6380-6385.
79. Wang, L., Tang, Y., Cole, P., and Marmorstein, R. (2008) Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr. Opin. Struct. Biol. 18, 741-747.
80. Bannister, A. J., and Kouzarides, T. (1996) The CBP co-activator is a histone acetyltransferase. Nature 384, 641-643.
81. Ogryzko, V. V., Schiltz, R. L., Russanova, V., Howard, B. H., and Nakatani, Y. (1996) The transcriptional coactivators p300 and CBP are histone acetyltransferases. Cell 87, 953-959.
82. Bedford, D. C., Kasper, L. H., Fukuyama, T., and Brindle, P. K. (2010) Target gene context influences the transcriptional requirement for the KAT3 family of CBP and p300 histone acetyltransferases. Epigenetics 5, 9-15.
83. Sachchidanand, Resnick-Silverman, L., Yan, S., Mutjaba, S., Liu, W.-J., Zeng, L., Manfredi, J. J., and Zhou, M.-M. (2006) Target structure-based discovery of small molecules that block human p53 and CREB binding protein association. Chem. Biol. 13, 81-90.
84. Gerona-navarro, G., Rodríguez-fernández, Y., Mujtaba, S., Patel, J., Zeng, L., Plotnikov, A. N., Osman, R., and Zhou, M. (2011) Rational design of cyclic peptide modulators of the transcriptional co-activator CBP: a new class of p53 inhibitors. J. Am. Chem. Soc. 133, 2040-2043.
85. Rooney, T. P. C., Filippakopoulos, P., Fedorov, O., Picaud, S., Cortopassi, W., Hay, D., Martin, S., Tumber, A., Rogers, C. M., Philpott, M., Wang, M., Thompson, A. L., Heightman, T. D., Pryde, D. C., Cook, A., Paton, R. S., Müller, S., Knapp, S., Brennan, P. E., and Conway, S. J. (2014) A series of potent CREBBP bromodomain ligands reveals an induced-fit pocket stabilized by a cation-π interaction. Angew. Chem., Int. Ed. 53, 6126-6130.
86. SGC (2014). I-CBP112: a CREBBP/EP300-selective chemical probe. http://www.thesgc.org/chemical-probes/ICBP112 (accessed November 19, 2014).
87. Fedorov, O., Lingard, H., Wells, C., Monteiro, O. P., Picaud, S., Keates, T., Yapp, C., Philpott, M., Martin, S. J., Felletar, I., Marsden, B. D., Filippakopoulos, P., Mu, S., Knapp, S., Brennan, P. E., Drive, R., and Ox, O. (2014) [1,2,4]Triazolo[4,3-a]phthalzines: inhibitors of diverse bromodomains. J. Med. Chem. 57, 462-476.
88. Chung, C.-W., and Nicodeme, E. (2011) Quinoline, azoloquinoline, triazolobenzodiazepine derivatives as bromodomain inhibitors for treating autoimmune and inflammatory diseases and their preparation. WO2011054843A1.
89. Albrecht, B. K., Harmange, J.-C., Cote, A., and Taylor, A. M. (2012) Bromodomain inhibitors and uses thereof. US20140296243.
90. Ruegg, U. T., and Burgess, G. M. (1989) Staurosporine, K-252 and UCN-01: potent but nonspecific inhibitors of protein kmases. Trends Pharmacol. Sci. 10, 218-220.
91. SGC (2014). Bromosporine. http://www.thesgc.org/chemical-probes/bromosporine (accessed November 19, 2014).
92. Ferguson, F. M., Fedorov, O., Chaikuad, A., Philpott, M., Muniz, J. R. C., Felletar, I., von Delft, F., Heightman, T., Knapp, S., Abell, C., and Ciulli, A. (2013) Targeting low-druggability bromodomains: fragment based screening and inhibitor design against the BAZ2B bromodomain. J. Med. Chem. 56, 10183-10187.
93. SGC (2014). GSK2801: A selective chemical probe for BAZ2B/A bromodomains. http://www.thesgc.org/chemical-probes/GSK2801 (accessed November 19, 2014).
94. SGC (2014). PFI-3: Selective chemical probe for SMARCA bromodomains. http://www.thesgc.org/chemical-probes/PFI-3 (accessed November 19, 2014).
95. Zhang, G., Sanchez, R., and Zhou, M.-M. (2012) Scaling the druggability landscape of human bromodomains, a new class of drug targets. J. Med. Chem. 55, 7342-7345.
96. Hopkinson, R. J., Walport, L. J., Münzel, M., Rose, N. R., Smart, T. J., Kawamura, A., Claridge, T. D. W., and Schofield, C. J. (2013) Is JmjC oxygenase catalysis limited to demethylation? Angew. Chem., Int. Ed. 52, 7709-7713.
97. Poplawski, A., Hu, K., Lee, W., Natesan, S., Peng, D., Carlson, S., Shi, X., Balaz, S., Markley, J. L., and Glass, K. C. (2014) Molecular insights into the recognition of N-terminal histone modifications by the BRPF1 bromodomain. J. Mol. Biol. 426, 1661-1676.
98. Muvva, C., Singam, E. R. A., Raman, S. S., and Subramanian, V. (2014) Structure-based virtual screening of novel, high-affinity BRD4 inhibitors. Mol. Biosyst. 10, 2384-2397.
99. Liu, Y., Wang, X., Zhang, J., Huang, H., Ding, B., Wu, J., and Shi, Y. (2008) Structural basis and binding properties of the second bromodomain of Brd4 with acetylated histone tails. Biochemistry 12, 6403-6417.
100. Zhao, H., Gartenmann, L., Dong, J., Spiliotopoulos, D., and Caflisch, A. (2014) Discovery of BRD4 bromodomain inhibitors by fragment-based high-throughput docking. Bioorg. Med. Chem. Lett. 24, 2493-2496.
101. Pantano, S., Marcello, A., Ferrari, A., Gaudiosi, D., Sabò, A., Pellegrini, V., Beltram, F., Giacca, M., and Carloni, P. (2006) Insights on HIV-1 Tat:P/CAF bromodomain molecular recognition from in vivo experiments and molecular dynamics simulations. Proteins 62, 1062-1073.
102. Eldridge, M. D., Murray, C. W., Auton, T. R., Paolini, G. V., and Mee, R. P. (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J. Comput.-Aided. Mol. Des. 11, 425-445.
103. Morris, G. M., Goodsell, D. S., Halliday, R. S., Huey, R., Hart, W. E., Belew, R. K., Olson, A. J., and Al, M. E. T. (1998) Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19, 1639-1662.
104. Huang, D., Rossini, E., Steiner, S., and Caflisch, A. (2014) Structured water molecules in the binding site of bromodomains can be displaced by cosolvent. ChemMedChem 9, 573-579.
105. MacKerell, a D., Bashford, D., Bellott, M., Dunbrack, R. L., Evanseck, J. D., Field, M. J., Fischer, S., Gao, J., Guo, H., Ha, S., Joseph-McCarthy, D., Kuchnir, L., Kuczera, K., Lau, F. T., Mattos, C., Michnick, S., Ngo, T., Nguyen, D. T., Prodhom, B., Reiher, W. E., Roux, B., Schlenkrich, M., Smith, J. C., Stote, R., Straub, J., Watanabe, M., Wiórkiewicz-Kuczera, J., Yin, D., and Karplus, M. (1998) All-atom empirical potential for molecular modeling and dynamics studies of proteins. J. Phys. Chem. B 102, 3586-3616.
106. Vidler, L. R., Filippakopoulos, P., Fedorov, O., Picaud, S., Martin, S., Tomsett, M., Woodward, H., Brown, N., Knapp, S., and Hoelder, S. (2013) Discovery of novel small-molecule inhibitors of BRD4 using structure-based virtual screening. J. Med. Chem. 56, 8073-8088.
107. Trellet, M., Melquiond, A. S. J., and Bonvin, A. M. J. J. (2013) A unified conformational selection and induced fit approach to protein-peptide docking. PLoS One 8, e58769.
108. Ferguson, F. M., Dias, D. M., Rodrigues, P. G. L. M., Wienk, H., Boelens, R., Bonvin, A. M. J. J., Abell, C., and Ciulli, A. (2014) Binding hotspots of BAZ2B bromodomain: Histone interaction revealed by solution NMR driven docking. Biochemistry 53, 6706-6716.
109. Vidler, L. R., Brown, N., Knapp, S., and Hoelder, S. (2012) Druggability analysis and structural classification of bromodomain acetyl-lysine binding sites. J. Med. Chem. 55, 7346-7359.
110. Halgren, T. (2009) Identifying and characterizing binding sites and assessing druggability. J. Chem. Inf. Model. 49, 377-389.
111. Halgren, T. (2007) New method for fast and accurate binding-site identification and analysis. Chem. Biol. Drug Des. 69, 146-148.
112. Steiner, S., Magno, A., Huang, D., and Caflisch, A. (2013) Does bromodomain flexibility influence histone recognition? FEBS Lett. 587, 2158-2163.
113. Mirguet, O., Lamotte, Y., Chung, C.-W., Bamborough, P., Delannée, D., Bouillot, A., Gellibert, F., Krysa, G., Lewis, A., Witherington, J., Huet, P., Dudit, Y., Trottet, L., and Nicodeme, E. (2014) Naphthyridines as novel BET family bromodomain inhibitors. ChemMedChem 9, 580-589.
114. Meslamani, J., Smith, S. G., Sanchez, R., and Zhou, M.-M. (2014) ChEpiMod: a knowledgebase for chemical modulators of epigenome reader domains. Bioinformatics 30, 1481-1483.
115. Gallivan, J. P., and Dougherty, D. (1999) Cation-pi interactions in structural biology. Proc. Natl. Acad. Sci. U.S.A. 96, 9459-9464.
116. Stigliani, J.-L., Bernardes-Génisson, V., Bernadou, J., and Pratviel, G. (2012) Cross-docking study on InhA inhibitors: a combination of Autodock Vina and PM6-DH2 simulations to retrieve bio-active conformations. Org. Biomol. Chem. 10, 6341-6349.
117. Chaires, J. B. (2008) Calorimetry and thermodynamics in drug design. Annu. Rev. Biophys. 37, 135-151.
118. Lea, W. A., and Simeonov, A. (2011) Fluorescence polarization assays in small molecule screening. Expert Opin. Drug Discovery 6, 17-32.
119. Silvestre, H. L., Blundell, T. L., Abell, C., and Ciulli, A. (2013) Integrated biophysical approach to fragment screening and validation for fragment-based lead discovery. Proc. Natl. Acad. Sci. U.S.A. 110, 12984-12989.
120. Chung, C.-W., and Witherington, J. (2011) Progress in the discovery of small-molecule inhibitors of bromodomain-histone interactions. J. Biomol. Screening 16, 1170-1185.
121. Hassan, A. H., Awad, S., Al-Natour, Z., Othman, S., Mustafa, F., and Rizvi, T. (2007) Selective recognition of acetylated histones by bromodomains in transcriptional co-activators. Biochem. J. 402, 125-133.
122. Hu, P., Wang, X., Zhang, B., Zhang, S., Wang, Q., and Wang, Z. (2014) Fluorescence polarization for the evaluation of small-molecule inhibitors of PCAF BRD/Tat-AcK50 association. ChemMedChem 9, 928-931.
123. Falconer, R. J., Penkova, A., Jelesarov, I., and Collins, B. M. (2010) Survey of the year 2008: applications of isothermal titration calorimetry. J. Mol. Recognit. 23, 395-413.
124. Tsai, W.-W., Wang, Z., Yiu, T. T., Akdemir, K. C., Xia, W., Winter, S., Tsai, C.-Y., Shi, X., Schwarzer, D., Plunkett, W., Aronow, B., Gozani, O., Fischle, W., Hung, M.-C., Patel, D. J., and Barton, M. C. (2010) TRIM24 links a non-canonical histone signature to breast cancer. Nature 468, 927-932.
125. Zeng, L., Li, J., Muller, M., Yan, S., Mujtaba, S., Pan, C., Wang, Z., and Zhou, M.-M. (2005) Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J. Am. Chem. Soc. 127, 2376-2377.
126. Kanno, T., Kanno, Y., Siegel, R. M., Jang, M. K., Lenardo, M. J., and Ozato, K. (2004) Selective recognition of acetylated histones by bromodomain proteins visualized in living cells. Mol. Cell 13, 33-43.
127. Philpott, M., Rogers, C. M., Yapp, C., Wells, C., Lambert, J.-P., Strain-Damerell, C., Burgess-Brown, N., Gingras, A.-C., Knapp, S., and Müller, S. (2014) Assessing cellular efficacy of bromodomain inhibitors using fluorescence recovery after photobleaching. Epigenetics Chromatin 7, 1-12.
128. Jung, M., Philpott, M., Müller, S., Schulze, J., Badock, V., Eberspächer, U., Moosmayer, D., Bader, B., Schmees, N., Fernández-Montalván, A., and Haendler, B. (2014) Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1. J. Biol. Chem. 289, 9304-9319.
129. Wu, J., Shin, J., Williams, C. M. M., Geoghegan, K. F., Wright, S. W., Limburg, D. C., Sahasrabudhe, P., Bonin, P. D., Lefker, B. a., and Ramsey, S. J. (2014) Design and chemoproteomic functional characterization of a chemical probe targeted to bromodomains of BET family proteins. MedChemComm 5, 1871-1878.
130. Demont, E. H., Bamborough, P., Chung, C., Craggs, P. D., Fallon, D., Gordon, L. J., Grandi, P., Hobbs, C. I., Hussain, J., Jones, E. J., Gall, A., Le Michon, A., Mitchell, D. J., Prinjha, R. K., Roberts, A. D., Sheppard, R. J., Watson, R. J., Road, P., and Sg, W. (2014) 1,3-Dimethyl benzimidazolones are potent, selective inhibitors of the BRPF1 bromodomain. ACS Med. Chem. Lett. 5, 1190-1195.
131. Chapuy, B., McKeown, M. R., Lin, C. Y., Monti, S., Roemer, M. G. M., Qi, J., Rahl, P. B., Sun, H. H., Yeda, K. T., Doench, J. G., Reichert, E., Kung, A. L., Rodig, S. J., Young, R., Shipp, M., and Bradner, J. E. (2013) Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell 24, 777-790.
132. Lovén, J., Hoke, H. a, Lin, C. Y., Lau, A., Orlando, D., Vakoc, C. R., Bradner, J. E., Lee, T. I., and Young, R. (2013) Selective inhibition of tumor oncogenes by disruption of super-enhancers. Cell 153, 320-334.
133. Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A., Hoke, H., and Young, R. (2013) Super-enhancers in the control of cell identity and disease. Cell 155, 934-47.
134. Tang, Y., Gholamin, S., Schubert, S., Willardson, M. I., Lee, A., Bandopadhayay, P., Bergthold, G., Masoud, S., Nguyen, B., Vue, N., Balansay, B., Yu, F., Oh, S., Woo, P., Chen, S., Ponnuswami, A., Monje, M., Atwood, S. X., Whitson, R. J., Mitra, S., Cheshier, S. H., Qi, J., Beroukhim, R., Tang, J. Y., Wechsler-Reya, R., Oro, A. E., Link, B. A., Bradner, J. E., and Cho, Y.-J. (2014) Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat. Med., 1-11.
135. Asangani, I. A., Dommeti, V. L., Wang, X., Malik, R., Cieslik, M., Yang, R., Escara-Wilke, J., Wilder-Romans, K., Dhanireddy, S., Engelke, C., Iyer, M. K., Jing, X., Wu, Y.-M., Cao, X., Qin, Z. S., Wang, S., Feng, F. Y., and Chinnaiyan, A. M. (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510, 278-282.
136. Lamoureux, F., Baud'huin, M., Rodriguez Calleja, L., Jacques, C., Berreur, M., Rédini, F., Lecanda, F., Bradner, J. E., Heymann, D., and Ory, B. (2014) Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. Nat. Commun. 5, 3511.
137. Rajagopalan, V., Vaidyanathan, M., and Bradner, J. E. (2014) Pre-clinical analysis of changes in intra-cellular biochemistry of glioblastoma multiforme (GBM) cells due to c-Myc silencing. Cell Mol. Neurobiol 34, 1059-1069.
138. Barrett, E., Brothers, S., Wahlestedt, C., and Beurel, E. (2014) I-BET151 selectively regulates IL-6 production. Biochim. Biophys. Acta 1842, 1549-1555.